Occam Recruits Daphne Karydas to the Board of Elicio

Elicio Therapeutics is advancing its ground-breaking Amphiphile technology across immunotherapy and vaccine platforms to develop therapies for cancer and infectious disease. The company went public in early 2023.

Daphne Karydas is currently COO & CFO of Flare Therapeutics, a private company that closed a $123M B round in March of 2023. Prior to joining Flare, Karydas was the Chief Financial Officer at Syndax Pharmaceuticals. Karydas has served as Senior Vice President of Corporate Financial Planning & Analysis and Strategy at Allergan plc, where she oversaw the company’s long-term financial and business strategy, until its acquisition by Abbvie in May 2020. She joined Allergan in April 2017 as Senior Vice President of Global Investor Relations and Strategy at Allergan, leading engagement with the investment community and business strategy development. Prior to joining Allergan, she served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management. Previously, she was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier, Ms. Karydas was a Vice President at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs’ healthcare investment banking team. Before joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co. where she focused on process development for novel vaccines. Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

‍